The global Host Cell Protein (HCP) Testing Market is experiencing significant growth, driven by increasing demand for biologics, advancements in analytical methods, and stringent regulatory frameworks. The market size was valued at USD 2.37 billion in 2024, grew to USD 2.56 billion in 2025, and is projected to reach approximately USD 5.19 billion by 2034, expanding at a CAGR of 8.17% between 2025 and 2034.
This article explores the market dynamics, key players, and future trends shaping the host cell protein testing landscape.
Growing Biologics Demand: With biologics accounting for a significant share of new drug approvals, robust HCP testing is vital for ensuring product safety and efficacy.
Technological Advancements: Innovations in ELISA, mass spectrometry, and high-throughput screening are improving detection sensitivity.
Regional Insights: North America dominated in 2024 with 41-45% market share, while Asia-Pacific is anticipated to be the fastest-growing region through 2034.
Segment Analysis: The ELISA segment led with a 36-40% share in 2024 and continues to be a preferred method due to its cost-effectiveness and ease of use.
About: A global leader in life science reagents and tools, Abcam focuses on enabling breakthroughs in scientific research.
Products: Provides high-quality antibodies, ELISA kits, and custom assay development for HCP detection.
Market Cap: Approx. USD 5.2 billion.
About: Alphalyse specializes in protein analysis and HCP identification services using advanced mass spectrometry.
Products: Custom HCP assays and mass spectrometry-based HCP analysis.
Market Cap: Privately held. Estimated revenue in millions.
About: German-based BioGenes is renowned for custom antibody development and HCP assay solutions.
Products: Offers ready-to-use and custom ELISA kits for HCP testing.
Market Cap: Private company with a niche market presence in bioanalytics.
About: A Sartorius subsidiary, BioOutsource delivers bioanalytical testing solutions globally.
Products: HCP ELISA assay kits and bioanalytical support for biologics manufacturers.
Market Cap: Sartorius parent company valuation over USD 20 billion.
About: Headquartered in the U.S., Bio-Techne provides tools for protein analysis and cell biology research.
Products: Offers ELISA kits, antibodies, and protein quantification tools for HCP testing.
Market Cap: Approx. USD 11 billion.
About: A global contract research organization (CRO) offering end-to-end drug discovery and development services.
Products: HCP testing services integrated into biologics safety testing programs.
Market Cap: Approx. USD 12 billion.
About: Pioneers in HCP assay development, Cygnus Technologies is highly regarded for its ELISA kits.
Products: Extensive portfolio of HCP ELISA kits and custom assay development.
Market Cap: Part of Maravai LifeSciences (USD 6 billion market cap).
About: One of the world’s largest bioanalytical testing providers, Eurofins offers comprehensive biologics testing services.
Products: Custom and platform HCP ELISA kits and LC-MS-based HCP analysis.
Market Cap: Approx. USD 15 billion.
About: Cytiva, under GE Healthcare, supports biopharmaceutical research with innovative technologies.
Products: HCP detection platforms and chromatography solutions.
Market Cap: Part of Danaher Corporation (USD 180 billion).
About: A multinational assurance and testing company providing regulatory and quality assurance for biopharmaceuticals.
Products: HCP testing and full bioanalytical support services.
Market Cap: Approx. USD 10 billion.
About: A key CDMO (Contract Development and Manufacturing Organization) serving the biopharma industry.
Products: Integrated HCP testing services as part of biologics development pipelines.
Market Cap: Approx. USD 45 billion.
About: A division of Merck KGaA, MilliporeSigma offers analytical and bio-processing solutions.
Products: HCP ELISA kits, sample preparation tools, and quality control assays.
Market Cap: Merck KGaA valuation approx. USD 95 billion.
About: Specializes in biologics testing services with a focus on regulatory compliance.
Products: HCP ELISA testing and bioanalytical laboratory support.
Market Cap: Privately held company.
About: Thermo Fisher’s subsidiary PPD delivers contract research and HCP testing services globally.
Products: Comprehensive biologics characterization and HCP detection solutions.
Market Cap: Thermo Fisher Scientific valuation over USD 210 billion.
About: Promega develops reagents and tools for life science research and diagnostics.
Products: HCP detection reagents and protein quantification assays.
Market Cap: Privately owned, estimated revenue over USD 800 million.
The HCP testing market is poised for transformative growth with advancements in genomics, high-throughput screening technologies, and regulatory demand for precision testing. Companies are expanding their global footprints to address rising biopharma production needs, especially in Asia-Pacific.
Request a customized case study tailored to your business needs and gain deeper insights
into healthcare market strategies: sales@towardshealthcare.com
Host cell protein testing detects residual proteins from host cells in biologics to ensure safety, efficacy, and regulatory compliance.
ELISA technology leads the market due to its cost-efficiency and widespread adoption.
Key players include Abcam, Bio-Techne, Lonza, MilliporeSigma, Eurofins Scientific, and Charles River Laboratories.
Growing biologics demand, stringent regulations, and advancements in analytical technologies drive market expansion.
Asia-Pacific is projected to grow at the fastest rate due to rising investments in biopharmaceutical manufacturing.
Source : https://www.towardshealthcare.com/insights/host-cell-protein-testing-market-sizing
Invest in Our Premium Strategic Solution: https://www.towardshealthcare.com/price/5865
🏥 Rapid Expansion of the Medical Device Sector Asia-Pacific’s orthopedic device market medical industry is experiencing an unprecedented boom. From… Read More
The global orthopedic device markett is witnessing transformative growth, fueled by technological advancements, an aging population, and rising demand for… Read More
North America seized 42% of the generative AI in life science market share in 2024. But what fueled this dominance?… Read More
San Diego, CA, July 18, 2025 Acadia Pharmaceuticals, a leader in treatments for neurological and rare diseases, has unveiled an… Read More
Warsaw, IN, July 18, 2025 – Zimmer Biomet Holdings, Inc., a leading innovator in medical technology, has announced a definitive… Read More
London, July 18, 2025 – ViiV Healthcare, a global leader in HIV-focused pharmaceutical innovation, unveiled data from its Phase 3b… Read More